New hope for rare blood cancers: experimental drug enters human trials

NCT ID NCT07465835

First seen Mar 23, 2026 · Last updated May 21, 2026 · Updated 9 times

Summary

This early-stage study tests an investigational drug called ELA026 in adults with T/NK cell cancers that have come back or not responded to prior treatments. The main goals are to check safety and find the right dose. About 84 participants will be enrolled across multiple centers. This is not a cure; the aim is to control the disease and manage side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • START, Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • University Hospitals Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • Yale New Haven Hospital

    RECRUITING

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.